Akebia Therapeutics Inc.
This article was originally published in Start Up
Executive SummaryAkebia Therapeutics believes that the shorter circulating half-life of its oral daily HIF-regulating compound, currently in Phase I trials, will keep it from over-stimulating EPO production, which is related to the cardiovascular and other safety issues faced by current injectable ESAs. Beyond its efforts with HIF and anemia, Akebia is also pursuing preclinical research on inhibitors of the human protein tyrosine phosphatase beta for vascular leakage.
You may also be interested in...
The upcoming Therapeutic Area Partnership conference will showcase companies in niche areas that are prime targets for partnerships or acquisitions.
Akebia will sell off, partner or possibly bring AKB-6548 – thought to be a safer erythropoietin stimulator than currently available injectables – through Phase III, while its spinout, Aerpio, will focus on clinical development of candidates for diabetic macular edema and inflammatory bowel disease.